

## Oxytocin Formulation

Version            Revision Date:            SDS Number:            Date of last issue: 04/09/2022  
2.7                10/01/2022                3447264-00010            Date of first issue: 09/26/2018

---

### SECTION 1. IDENTIFICATION

Product name                                : Oxytocin Formulation

#### Manufacturer or supplier's details

Company name of supplier                : Merck & Co., Inc  
Address                                        : 126 E. Lincoln Avenue  
    : Rahway, New Jersey U.S.A. 07065  
Telephone                                    : 908-740-4000  
Emergency telephone                      : 1-908-423-6000  
E-mail address                               : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use                         : Veterinary product

Restrictions on use                        : Not applicable

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Not a hazardous substance or mixture.

#### GHS label elements

Not a hazardous substance or mixture.

#### Other hazards

None known.

---

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture                        : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Oxytocin, monoacetate (salt)	6233-83-6	< 0.1

Actual concentration is withheld as a trade secret

---

### SECTION 4. FIRST AID MEASURES

If inhaled                                    : If inhaled, remove to fresh air.  
    : Get medical attention if symptoms occur.

In case of skin contact                    : Wash with water and soap as a precaution.  
    : Get medical attention if symptoms occur.

In case of eye contact                     : Flush eyes with water as a precaution.  
    : Get medical attention if irritation develops and persists.

If swallowed                                 : If swallowed, DO NOT induce vomiting.  
    : Get medical attention if symptoms occur.  
    : Rinse mouth thoroughly with water.

Most important symptoms                 : None known.  
and effects, both acute and  
delayed

Protection of first-aiders                 : No special precautions are necessary for first aid responders.

---



## Oxytocin Formulation

Version 2.7      Revision Date: 10/01/2022      SDS Number: 3447264-00010      Date of last issue: 04/09/2022  
 Date of first issue: 09/26/2018

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Oxytocin, monoacetate (salt)	6233-83-6	STEL	50 ng/m <sup>3</sup> (OEB 5)	Internal
		Wipe limit	60 ng/100 cm <sup>2</sup>	Internal

- Engineering measures** : Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 No open handling permitted.  
 Totally enclosed processes and materials transport systems are required.  
 Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

#### Personal protective equipment

- Respiratory protection : No personal respiratory protective equipment normally required.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.  
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.  
 Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

# SAFETY DATA SHEET



## Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
2.7	10/01/2022	3447264-00010	Date of first issue: 09/26/2018

---

Hygiene measures : disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.  
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	liquid
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available

**Oxytocin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
2.7	10/01/2022	3447264-00010	Date of first issue: 09/26/2018

---

Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	Not applicable

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Information on likely routes of exposure**

Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****Oxytocin, monoacetate (salt):**

Acute oral toxicity	:	LD50 (Mouse): > 514 mg/kg
		LD50 (Rat): > 21 mg/kg
Acute toxicity (other routes of administration)	:	LD50 (Mouse): > 514 mg/kg Application Route: Subcutaneous
		LD50 (Mouse): 5.8 mg/kg Application Route: Intravenous

---

**Oxytocin Formulation**

Version 2.7      Revision Date: 10/01/2022      SDS Number: 3447264-00010      Date of last issue: 04/09/2022  
Date of first issue: 09/26/2018

---

LD50 (Rat): > 21 mg/kg  
Application Route: Subcutaneous

LD50 (Rat): 2.3 mg/kg  
Application Route: Intravenous

**Skin corrosion/irritation**

Not classified based on available information.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Oxytocin, monoacetate (salt):**

Genotoxicity in vitro : Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

Not classified based on available information.

**Components:****Oxytocin, monoacetate (salt):**

Effects on fetal development : Test Type: Development  
Species: Rat  
Application Route: Subcutaneous  
Developmental Toxicity: NOAEL: 1 mg/kg body weight  
Result: No effects on fetal development.

Reproductive toxicity - Assessment : May damage the unborn child.

**Oxytocin Formulation**

Version 2.7      Revision Date: 10/01/2022      SDS Number: 3447264-00010      Date of last issue: 04/09/2022  
Date of first issue: 09/26/2018

---

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Oxytocin, monoacetate (salt):**

Species : Rat  
LOAEL : 5 µg/kg  
Application Route : Subcutaneous  
Exposure time : 5 Days  
Target Organs : Endocrine system

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Oxytocin, monoacetate (salt):**

Inhalation : Target Organs: Central nervous system  
Symptoms: behavioral abnormalities  
Target Organs: Cardio-vascular system  
Symptoms: Increased heart rate, May cause cardiac arrhythmia., hypotension, tachycardia, flushing  
Target Organs: Gastrointestinal tract  
Symptoms: Nausea, Vomiting

Ingestion : Target Organs: Central nervous system  
Symptoms: behavioral abnormalities  
Target Organs: Cardio-vascular system  
Symptoms: Increased heart rate, May cause cardiac arrhythmia., hypotension, tachycardia, flushing  
Target Organs: Gastrointestinal tract  
Symptoms: Nausea, Vomiting

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Oxytocin, monoacetate (salt):****Ecotoxicology Assessment**

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

**Persistence and degradability**

No data available

## Oxytocin Formulation

Version 2.7      Revision Date: 10/01/2022      SDS Number: 3447264-00010      Date of last issue: 04/09/2022  
Date of first issue: 09/26/2018

---

### Bioaccumulative potential

#### Components:

#### **Oxytocin, monoacetate (salt):**

Partition coefficient: n-octanol/water : log Pow: 6.27

#### **Mobility in soil**

No data available

#### **Other adverse effects**

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### **Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### **International Regulations**

#### **UNRTDG**

Not regulated as a dangerous good

#### **IATA-DGR**

Not regulated as a dangerous good

#### **IMDG-Code**

Not regulated as a dangerous good

#### **Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

#### **Domestic regulation**

#### **49 CFR**

Not regulated as a dangerous good

#### **Special precautions for user**

Not applicable

---

## SECTION 15. REGULATORY INFORMATION

### **CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

### **SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

### **SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

This material does not contain any components with a section 302 EHS TPQ.

---



## Oxytocin Formulation

Version 2.7      Revision Date: 10/01/2022      SDS Number: 3447264-00010      Date of last issue: 04/09/2022  
 Date of first issue: 09/26/2018

**SARA 311/312 Hazards** : No SARA Hazards

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

**US State Regulations****Pennsylvania Right To Know**

Water


7732-18-5

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**SECTION 16. OTHER INFORMATION****Further information****NFPA 704:****HMIS® IV:**

<b>HEALTH</b>	/	0
<b>FLAMMABILITY</b>		1
<b>PHYSICAL HAZARD</b>		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "/" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-

## Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
2.7	10/01/2022	3447264-00010	Date of first issue: 09/26/2018

---

tem; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 10/01/2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8